The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) ##STR00001##
wherein Ar, X, X.sup.1, R.sup.1, R.sup.2, R.sup.3, m, n and the dotted line are as defined herein which compounds are useful for treating certain central nervous system disorders as described herein.

The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) ##STR00001##
wherein Ar, X, X.sup.1, R.sup.1, R.sup.2, R.sup.3, m, n and the dotted line are as defined herein which compounds are useful for treating certain central nervous system disorders as described herein.

This invention relates to modifications of -1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response.

##STR00001##

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.